S. Botton

发表

Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma

J. Bourhis, S. Broutin, A. Paci, 2015 .

AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo

Hua Yang, K. Yen, O. Bernard, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent Inhibitor of the IDH2 Mutant Metabolic Enzyme, Induces Durable Remissions in a Phase I Study in Patients with IDH2 Mutation Positive Advanced Hematologic Malignancies

Manish R. Patel, I. Flinn, R. Collins, 2014 .

Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference

L. Zitvogel, G. Kroemer, N. Chaput, 2007, Journal of Molecular Medicine.

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

R. Bouabdallah, H. Dombret, S. Chevret, 2007, Leukemia.

Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial

Manish R. Patel, I. Flinn, R. Collins, 2015 .

megakaryocytes Platelet formation is the consequence of caspase activation within

G. Kroemer, W. Vainchenker, N. Debili, 2013 .

Dissociated responses to newer antimyeloma drugs identify a subset of refractory patients with an extremely poor prognosis.

F. Pasquier, J. Bourhis, X. Mariette, 2013, European journal of cancer.

Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

G. Kroemer, P. Fenaux, L. Adès, 2008, Apoptosis.

Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

G. Kroemer, P. Fenaux, L. Adès, 2015, Apoptosis.

Effect of priming with granulocyte–macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group

J. Bourhis, H. Dombret, B. Quesnel, 2007, Leukemia.

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

P. Opolon, Hua Yang, K. Yen, 2014 .

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

M. Heuser, F. Thol, A. Ganser, 2012, Leukemia.

Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)

C. Preudhomme, P. Fenaux, F. Bauters, 2005, Leukemia.

Prognostic value of minimal residual disease by real-time quantitative PCR in acute myeloid leukemia with CBFB-MYH11 rearrangement: the French experience

J. Cayuela, H. Dombret, E. Macintyre, 2010, Leukemia.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias

D. Birnbaum, E. Solary, O. Bernard, 2013, Leukemia.

Response to Azacytidine (AZA) in MDS or AML with Del 5q : Current Results of the French ATU Program

A. Stamatoullas, E. Solary, B. Quesnel, 2008 .

Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia

H. Dombret, H. Tilly, C. Bastard, 2005, Bone Marrow Transplantation.

com-Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

E. Estey, R. Schlenk, R. Hills, 2019 .

Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program.

H. Dombret, A. Stamatoullas, B. Quesnel, 2009 .

P033 Isolated del 20q defines a subgroup of MDS patients with lower blast counts and more frequent thrombocytopenia

S. Chevret, P. Fenaux, L. Adès, 2009 .

Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program.

P. Fenaux, N. Vey, Sophie Park, 2006 .

AZA In the Treatment of Therapy Related MDS and AML (tMDS/AML): a Report on 60 Patients by the Groupe Francophone Des Syndromes Myelodysplasiques (GFM)

B. Quesnel, P. Fenaux, S. Thépot, 2010 .

Azacytidine (AZA) in MDS (including RAEB-t and CMML) in Patients (pts) ≥ 80 Years: Results of the French ATU Program.

B. Quesnel, E. Wattel, P. Fenaux, 2009 .

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

H. Dombret, A. Stamatoullas, L. Mannone, 2006 .

A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial

A. Stamatoullas, S. Chevret, B. Quesnel, 2018, Blood.

Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50–70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA)

H. Dombret, S. Chevret, C. Preudhomme, 2011 .

Randomized Comparison of Standard Induction with Daunorubicin (DNR) for 3 Days vs Idarubicin (IDA) for 3 or 4 Days in AML pts Aged 50 to 70 and of Maintenance with Interleukin 2. Final Analysis of the ALFA 9801 Study.

J. Bourhis, H. Dombret, S. Chevret, 2007 .

Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant- IDH2 (m IDH2) Acute Myeloid Leukemia (AML)

R. Collins, H. Kantarjian, M. Tallman, 2017 .

Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study

I. Flinn, R. Collins, A. Derti, 2015 .

Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials)

H. Dombret, A. Vekhoff, S. Chevret, 2006, Leukemia.

Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials).

H. Dombret, A. Vekhoff, S. Chevret, 2005 .

Myeloid-Derived Suppressive Cells Belonging to the Leukemic Clone Account for Immunosuppression In CMML

E. Solary, W. Vainchenker, B. Quesnel, 2010 .

Which AML Subsets Benefit from Leukemic Cell Priming during Chemotherapy? Long-Term Analysis of the ALFA-9802 GM-CSF Study

J. Bourhis, H. Dombret, C. Preudhomme, 2008 .

Is AraC Required In the Treatment of Standard Risk APL? Long Term Results of a Randomized Trial (APL 2000) From the French Belgian Swiss APL Group

H. Dombret, A. Stamatoullas, S. Chevret, 2010 .

Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.

E. Wattel, P. Fenaux, M. Sébert, 2009 .

Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)

H. Dombret, A. Baruchel, G. Leverger, 2006, Leukemia.

Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412)

H. Dombret, S. Chevret, C. Preudhomme, 2015 .

Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

H. Dombret, B. Quesnel, P. Fenaux, 2012, Leukemia & lymphoma.

Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association

H. Dombret, C. Preudhomme, P. Fenaux, 2011, Leukemia.

Incidence, Clinical Features, and Outcome of AllTrans-Retinoic Acid Syndrome in 413 Cases of Newly Diagnosed Acute Promyelocytic Leukemia

J. Miguel, H. Dombret, C. Chastang, 1998 .

Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group

H. Dombret, A. Vekhoff, S. Chevret, 2005, Leukemia.

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

A. Vekhoff, D. DeAngelo, C. Dumontet, 2012, Investigational New Drugs.

comparison of French-Belgian-Swiss and PETHEMA results Treatment of newly diagnosed acute promyelocytic leukemia (APL): a

H. Dombret, A. Vekhoff, E. Vellenga, 2013 .

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial.

J. Miguel, H. Dombret, A. Stamatoullas, 2000 .

Retinoic Acid Syndrome

P. Fenaux, S. Botton, 1998, Drug safety.

Enasidenib in mutant IDH 2 relapsed or refractory acute myeloid leukemia

I. Flinn, P. Vyas, K. Yen, 2017 .

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

P. Fenaux, T. Cluzeau, J. Liesveld, 2020 .

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

T. Cluzeau, J. Liesveld, P. Rousselot, 2020 .

ATM mediates constitutive NF-κB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

G. Kroemer, P. Fenaux, J. Perfettini, 2009, Oncogene.

Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study

H. Dombret, A. Delannoy, J. Gabert, 2006, Leukemia.

Extramedullary relapse in acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

H. Dombret, S. Chevret, B. Quesnel, 2006, Leukemia.

Abstract CT103: Clinical safety and activity in a phase I trial of AG-221, a first in class, potent inhibitor of the IDH2-mutant protein, in patients with IDH2 mutant positive advanced hematologic malignancies

I. Flinn, Hua Yang, R. Levine, 2014 .

Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome

L. Galluzzi, G. Kroemer, W. Hofmann, 2009, Oncogene.

Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1

I. Flinn, R. Collins, S. Choe, 2016 .

Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience

J. Miguel, J. Bourhis, H. Dombret, 2005, Leukemia.

Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study

R. Collins, K. Yen, H. Kantarjian, 2017 .

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

H. Döhner, P. Vyas, H. Kantarjian, 2019, Blood.

Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia

L. Galluzzi, G. Kroemer, P. Fenaux, 2013, Oncogene.

Preliminary Data on a Phase 1/2A First in Human Study of the Menin-KMT2A (MLL) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

P. Fenaux, A. Fathi, J. Altman, 2020 .

Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.

J. Cayuela, H. Dombret, A. Vekhoff, 2004 .

Effect of Priming with Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Younger Adults with Newly Diagnosed Acute Myeloid Leukemia (AML): A Trial by the Acute Leukemia French Association (ALFA) Group.

J. Bourhis, H. Dombret, B. Quesnel, 2005 .

Incidence and Prognosis of RTKs and RAS Mutations in CBF AML. A Retrospective Study of French Adult ALFA and Pediatric LAME Trials.

H. Dombret, A. Baruchel, T. Leblanc, 2004 .

Targeting Acute Myeloid Leukemia with a New CXCR4 Antagonist IgG1 Antibody (PF-06747143)in NOD/SCID Mice

W. Vainchenker, T. Smeal, O. Legrand, 2015 .

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

D. Birnbaum, E. Solary, O. Bernard, 2013 .

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

J. Esteve, J. Cortes, A. Khwaja, 2021 .

Spontaneous molecular response of IDH2 acute myeloid leukemia

C. Marzac, J. Micol, V. Saada, 2019, Annals of Hematology.

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia

S. Choe, L. Dang, H. Kantarjian, 2019, Blood.

Prognostic Significance of Concurrent Gene Mutations in Intensively Treated Patients with IDH1/2 Mutated AML

H. Dombret, C. Preudhomme, L. Adès, 2019, Blood.

Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML).

P. Vyas, O. Frankfurt, H. Kantarjian, 2019, Journal of Clinical Oncology.

Long‐term follow‐up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and Daunorubicin in the treatment of nonelderly APL patients

H. Dombret, A. Vekhoff, S. Chevret, 2013, American journal of hematology.

Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial

J. Miguel, H. Dombret, A. Vekhoff, 2003, Leukemia.

Gemtuzumab Ozogamicin-Based Salvage, Followed by Allogeneic Hematopoietic Stem Cell Transplantation, Is Highly Effective in Young Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Relapse

H. Dombret, J. Tamburini, T. Cluzeau, 2011 .

PS1051 FT-2102, AN IDH1 M INHIBITOR, INDUCES MUTATION CLEARANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) TREATED IN PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

J. Cortes, G. Schiller, K. Seiter, 2019, HemaSphere.

Autoimmune hemolytic anemias and IgG antierythrocyte autoantibodies in Waldenström's macroglobulinemia: association with FcγRIIa polymorphism

I. Dervite, P. Morel, X. Leleu, 2006, Leukemia.

Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML).

H. Döhner, P. Vyas, H. Kantarjian, 2020 .

Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

H. Döhner, P. Vyas, O. Frankfurt, 2019, Clinical Lymphoma Myeloma and Leukemia.

Intervention combining nurse navigators (NNs) and a mobile application versus standard of care (SOC) in cancer patients (pts) treated with oral anticancer agents (OAA): Results of CapRI, a single-center, randomized phase III trial.

A. Fourcade, D. Planchard, O. Mir, 2020 .

Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

S. Carr, B. Ebert, J. Cayuela, 2021, Blood cancer discovery.

BCOR and BCORL 1 mutations in myelodysplastic syndromes and related disorders

D. Birnbaum, S. Miyano, Y. Shiraishi, 2013 .

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL)

H. Dombret, P. Chevallier, D. Blaise, 2013 .

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

S. Choe, K. Yen, H. Kantarjian, 2018, Blood.

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

S. Choe, K. Yen, H. Kantarjian, 2018, Blood.

Survival Improvement in Therapy Related Myeloid Neosplasm ? a Single Center Analysis of 428 Patients

J. Bourhis, E. Solary, S. Koscielny, 2016 .

F. Pasquier, C. Guillouf, F. Rosselli, 2020 .

O11.3Targeting isocitrate dehydrogenase (IDH)1 and IDH2 mutations Clinical results in advanced hematologic malignancies

S. Botton, 2015 .

Erratum to: Flt3 receptor inhibition reduces constitutive NFκB activation in high-risk myelodysplastic syndrome and acute myeloid leukemia

G. Kroemer, P. Fenaux, L. Adès, 2008, Apoptosis.

Impact of ATRA Duration during the Induction Treatment of Newly Diagnosed APL

H. Dombret, A. Vekhoff, S. Chevret, 2008 .

1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies

Hua Yang, M. Tallman, R. Stone, 2014 .

Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.

A. Baruchel, G. Leverger, S. Chevret, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.

J. Bourhis, H. Dombret, S. Chevret, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL): A Comparison between French -Belgian-Swiss and Spanish Results.

H. Dombret, A. Vekhoff, E. Vellenga, 2005 .

Is ARAC Required in the Treatment of Newly Diagnosed APL? Results of a Randomized Trial (APL 2000).

H. Dombret, A. Stamatoullas, A. Vekhoff, 2004 .

Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia

L. Zitvogel, O. Kepp, G. Kroemer, 2010, Cell Death and Disease.

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

J. Cortes, J. Liesveld, A. Raza, 2018, Blood.

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

A. Krainer, Shouyong Peng, E. Wagner, 2017 .

Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes (MDS)

R. Collins, H. Kantarjian, M. Tallman, 2016 .

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

J. Miguel, H. Dombret, C. Chastang, 1998, Blood.

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.

H. Dombret, A. Stamatoullas, L. Mannone, 2008, Leukemia research.